I believe we should use topica l rather than sys temic age nts as first-line therapy for infec tions in patients wit h perforated tympanic membranes.
rubbing the dro pper in your hand s or by immersing it in tepi d wate r for a few minutes.
Direct contact. Another potential disadvantage is that the rapy necessitates that the dro ps come into direct contact with infected tiss ue. However, the external auditory cana l mig ht be so filled with desq uamated epithelium, cerumen, and mucopuru lence that medications cannot effectively reach the target tissues. Therefore, if topical therapy is to be effective, these materials must be removed. This can be accomplished in the physician's office by mechanical removal or by gentle irrigat ion with 3% hydrogen peroxide at full or half strength.
Inflammation. Some medications have direct inflammatory effects. They include some antibiotics, as well as vehicles such as propy lene glycol. Because inflammation is already part ofthe pathologic process, additional inflammation is an undesirable side effect that shou ld be minimized or counteracted. The stero id component present in many preparations can serve this functio n.
Sys temic effects. If a syste mic effect is desirab le, then, of course , the absence of a sys tem ic effec t is a disadvant age. For example, if infection has spread beyond the exte rna l auditory cana l and the middle ear, topical preparations will not be effective. Other examples ofsuch a sit uation inclu de bac teria l external otit is that has spread to the per iauricular areas with cellulitis, otitis that disseminates to regional lymph nodes, and otitis media that deve lops into masto iditis. Fortunately, these circ umstances are uncommon, and there is usually no need for systemic medication.
Ototoxicity. The aminoglycoside antibiotics and pol ymyxin B are devastatingly ototoxic in animals. A single dose of neomycin/polymyxin B/hydrocortisone into the external auditory cana l ofa chinchilla passes easily through a tympanostomy tube and produces a significant loss of hair cells in the basal turn of the cochlea. ' Even a single dose of antibiotic drops instilled directly into the middle ear can prod uce total hair-ce ll loss. ' .
The extent to wh ich these anima l data can be extrapo lated to humans has always been a source of spec ulatio n. The incidence ofheari ng loss associated wit h the use ofototox ic drops is cer tain ly less catastrophic in humans, but a number of case reports do exist.' Researchers at the University of In 1990, they reported their study of three gro ups of 20 adu lts who were randomized to receive one of three regimens for 5 to 10 days." O ne group rece ived ora l ciprofloxac in at 250 mg tw ice daily, ano ther received 3 drops of ciprofloxacin (250 ug/rnl in a sa line solution) twice a day, and the third received both the ora l and topical ciprofloxacin doses twice a day. The topical group had a cli nical response rate of 100% and a bacteriologic cure rate of95%, and the topical/oral group had rates of 95 and 85%, respective ly. By contrast, the ora l gro up ha d corresponding rates of 65 and 40%, a stat istica lly significa nt difference. W hen clin ica l and bacteriologic cure rates were com bined , the differences between the topical gro ups and the ora l group were also statistically significant (p < 0.05) (figure I ).
Two years later, Esposito et al publ ished the results of their comparison of topical ciprofloxacin and intramuscular gentamicin in 60 adults.' A ll pat ients had perforated ear drums an d Pseudomonas infection susceptible in vitro to both agents, and no ne had cholesteatoma; 40 of them had previously undergone sys temic therapy. Hal f the group was randomized to receive 4 drops of ciprofloxacin (250 ug /m l in a sa line so lut ion) twice a day for 5 to 10 days, and the other half received twice-dai ly 80-mg injections of ge ntamicin for 5 to 10 days. Patients were assessed clinically and microbiologically 12 ho urs fo llow ing the cessation of treatment and again 2 to 3 weeks later. Favorable clinical responses were seen in 26 ciprofloxacin patients (87%) and in 20 gentamicin patients (67%). Only 13 gen ta micin patients (43%) ach ieved microb iologic eradication, compared wi th 25 ciprofloxacin patien ts (83%) (figure 2).
Another advantage of ototopicals is that they can alter the microenvironme nt (I) by changing the pH; (2) by removing debris, puru lence, and cerumen wit hin the canal; and (3) by the actions of the ir emollient effects. Finally, oto topicals are ge nerally less expensive than systemic equivalents. ear space.
Advantages of ototopicals
By using a topical agent, the physician can de liver a co nce ntration ofmedicat ion that is several orders ofmag nitude highe r than the co ncentration of a systemic agent. Topical de livery systems maximize the therapeutic ratio.
A 3-to 5-drop dose of 0.3% so lut ion con tai ns on ly 90 to 150 ug of ant ibiotic, but its co ncentration is 3,000 ug/rnl, which exceeds the m inim um inhibitory concentration of any known relevant pathogen . In contrast, co nsider the typ ica l drug level s in midd le ear fluid that can be achieved by three sys temic antibiotics:
Toro nto have demonstrated tha t vestibu lar tox icity may be significantly higher.A recent consensus panel convened by theAmericanAcademy ofOto laryngology-Head and Neck Surgery has therefore recom mended that antibiotic drops that are not po tentially ototoxic shou ld be used instead of dro ps that might cause inner ear injury (page 13).4
Se nsitization. The aminoglycosides and especially neomycin have a propensity to cause topical sensitizat ion. Whi le fulminant hypersensitivity reactions are usuall y relatively easy to recognize, hypersensitivity may take a more sub tle form. Oftentimes, the on ly man ifes tations of hy persensitivity are persistent erythema, edema, and otorrhea, which simply represent a fai lure ofthe ear to res pond to therapy. In such circumstances, it may be impossible to d istingu ish between hyp ersensitivity reactions and cl in ica l treatment fai lures. 
Topicals in CSOM
Two other studies of note looked at the efficacy of topica l fluoroquino lones in chronic suppurative otitis media (CSOM). In 1994, Yuen at al published the results of their prospective comparison of topica l 0.3% ofloxac in and ora l amoxici llin/c1avulanate in 56 patients.' One wee k after the completion of treatm ent, 76% of the ofloxac in group had dry ears, compared with only 26% of the other gro up.
Three years later, Fradis et al reported the findings of their placebo-controlled study oftopica l ciprofloxac in and topica l tobramyci n.?P aeruginosa was the most co mmon isolate. A total of5 I patie nts (60 ears) with CS OM witho ut cho lesteatoma were randomized to take one of the three preparations at 5 drops 3 times a day for 3 weeks. At the comp letion of therapy, a clinical response was seen in 79, 72, and 41% of the ears , respectively; corresponding bacteriologic cure rates were 67,67, and 20%. The sensitivity of P aeruginosa to ciprofloxacin and tobramycin was 94 and 7 I%, respectively.
Antibiotic/ steroid combinations in AOMT
Two studies have shown that the additio n of a steroid to a quinolone is more effective than quino lone monotherapy in the treatment ofchildren wit h acute otitis media through tymp anostomy tubes (AOM T).
A combination of 0.3% ciprofloxacin and 0.1% dexamethasone was compared with ciprofloxac in alone in a patient-blinded, parallel-group , mult icenter study of 20 1 patients aged 6 months to 12 years withAOMTof3 weeks ' durat ion or less and with visible otorrhea.10 Patients were rando mize d to receive their respective drops twice daily for 7 days . Patients were eval uated on days 1,3, 8, and 14 (test-of-cure visit). Patients or their pare nts also kept diaries to record the status of their otorrhea tw ice a day. Of the 20 I patien ts, 167 were microbiologically culture-posi tive. Among this subgro up, the time to cess ation of otorr hea was significantly shorter among those who had received the comb ination drop (4.22 vs. 5.3 1 days;p = 0.004); the combination-therapy group also exhibited significantly better clinica l responses on days 3 and 8 (p < 0.0001 and p < 0.0499 , respect ively). At the test -of-cure visit, clinica l and microbiologic cure rates in the two groups were similar. The authors concluded that the benefit of adding the steroid, which led to a 20% reduction in the time to cessation of otorrhea, is clinically meaningful.
In a similar study, topical ciprofloxacin/dexamethasone otic suspension and ofloxacin otic solution were compared in 599 pat ients-aged 6 months to 12 years (mean: 2.5 yr)-with AOMT of3 weeks ' duration or less.II Patients were random ized to receive the same ciprofloxacin/dexamethasone combi nation (4 drops twice dai ly for 7 days) or 0.3% ofloxac in (5 drops twice daily for 10days, which is its indica ted dosage).According to findings at the test-of-cure visit (day 18), ciprofloxacin/dexamethaso ne was superior to ofloxaci n in terms of clinical (overall 86 vs. 79% and for culture pos itive patients 90 vs. 78%) and microbiologic (92 vs. 8 1.8%) cure. Treat ment failure rates were 4.4 and
